<DOC>
	<DOCNO>NCT01205022</DOCNO>
	<brief_summary>RATIONALE : Radiolabeled monoclonal antibody find tumor cell either kill carry tumor-killing substance without harm normal cell . Giving radioactive substance together antibody may effective treatment advance cancer . Drugs use chemotherapy , irinotecan hydrochloride , fluorouracil , leucovorin calcium ( FOLFIRI ) , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Bevacizumab may also stop growth tumor cell block blood flow tumor . Giving radiolabeled monoclonal antibody together combination chemotherapy bevacizumab may effective treatment colorectal cancer . PURPOSE : This phase I trial study side effect , best way give , best dose yttrium Y 90 DOTA anti-CEA ( Carcinoembryonic antigen ) monoclonal antibody M5A give together combination chemotherapy bevacizumab treat patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Radiolabeled Monoclonal Antibody Therapy , Combination Chemotherapy , Bevacizumab Treating Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerate dose combination FOLFIRI chemotherapy , intravenous yttrium-90 ( 90Y ) M5A anti-CEA antibody . SECONDARY OBJECTIVES : I . To study progression free survival response rate combine treatment patient stage IV colorectal cancer.II . To evaluate biodistribution , clearance metabolism 90Y 111In ( indium-111 ) M5A administer intravenously . OUTLINE : This dose-escalation study yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A . Patients receive irinotecan hydrochloride IV 90 minute , leucovorin calcium IV 2 hour , fluorouracil IV continuously 46-48 hour , bevacizumab IV 30-90 minute every 2 week . Patients also receive yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A IV 25 minute week 3 9 . Treatment continue absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>Patients must Karnofsky performance status &gt; 60 % Patients must histological confirmation colorectal carcinoma stage IV disease unresectable disease Patients must colorectal tumor produce CEA document either immunohistochemistry elevate serum CEA Prior radiotherapy , immunotherapy , chemotherapy must complete less 28 day prior patient entry study patient must recover acute expect side effect prior therapy . For patient undergone port placement , study treatment initiation must least 7 day post port placement Adequate bone marrow function evidence hemoglobin &gt; 10 g/dL , WBC &gt; 4000/ul , absolute granulocyte count &gt; 1,500/mm^3 , platelet &gt; 150,000/ul ; patient may transfuse reach hemoglobin &gt; 10 g/dL In doseescalation phase , patient may history prior malignancy ; doseexpansion cohort , patient may history prior malignancy disease free five year exception basal squamous cell skin cancer carcinoma situ cervix Patients must total bilirubin &lt; 1.5 mg/dL serum creatinine &lt; 2.0 mg/dL If patient previously receive antibody , serum antiantibody test must negative Serum HIV test hepatitis B surface antigen C antibody test must negative Women childbearing potential must negative serum pregnancy test prior entry study must practice effective form contraception Patients must measurable disease define modified RECIST criterion Patients receive radiation therapy great 50 % bone marrow Patients nonmalignant intercurrent illness ( example cardiovascular , pulmonary , central nervous system disease ) either poorly control currently available treatment severity investigator deem unwise enter patient protocol shall ineligible Patients &gt; 2+ protein dipstick undergo 24 hour urine collection ; patient &gt; 1gram proteinuria/ 24 hour eligible Patients may receive neoadjuvant and/or adjuvant chemotherapy and/or radiotherapy present study relapse ; otherwise , prior therapy allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>